stockrow
Saturday 7 November 2026
Export WINT’s income statement to Excel — free account
Windtree Therapeutics, Inc.
WINT Healthcare Biotechnology
- EPS
- +99.5%
- Free cash flow
- +1.12%
Quarter to September 2025, against a year earlier
0.00
0.00
NaN
Follow WINT
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM Sep ’25 | Trend | 10 yrs | 2025e | 2026e | 2027e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | 2 | 1 | 2 | 0 | — | — | — | — | — | 1 | (54.1%) | 12 | — | — | — | |
| Gross margin, % | — | 100.00 | 100.00 | 100.00 | 100.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | (100.0) pt | ||||||
| EBT | — | (39) | (18) | (21) | (27) | (33) | (78) | (41) | (20) | (2) | (44) | (32.1%) | ||||||
| EBT margin, % | — | (1,933.89) | (1,242.15) | (1,148.38) | (13,876.26) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +1,933.9 pt | ||||||
| Net income | — | (39) | (18) | (21) | (27) | (33) | (68) | (39) | (20) | (2) | (40) | (32.1%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | 4.91 | 1.44 | 0.40 | 815.35 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | (94.93) | (3,258,957.00) | (1,044,303.00) | (113,138.30) | (93,525.19) | (122,751.80) | (55,962.23) | (4,712.23) | (104.35) | (8.37) | +1.2% | ||||||
| Cash flow | — | (80.74) | (20.47) | (3.51) | (101,560.70) | (72,771.44) | (39,440.00) | (27,788.57) | (3,124.88) | (292.81) | (0.57) | +17.5% | ||||||
| Capex | — | (0.61) | (0.02) | 0.00 | (786.53) | (836.52) | (465.00) | 281.43 | (3.49) | (0.23) | 0.00 | (11.6%) | ||||||
| Free cash flow | — | (81.35) | (20.50) | (3.51) | (102,347.22) | (73,607.96) | (39,905.00) | (27,507.14) | (3,128.37) | (293.04) | (0.57) | +17.4% | ||||||
| Book value | — | (69.30) | (23.27) | 15.16 | 308,577.66 | 199,936.76 | 69,801.67 | 14,302.86 | 788.60 | 190.04 | (0.44) | n/m | ||||||
| Shares, m | — | 0 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | (22.8%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | 0.00 | 0.0 | |||||
| P/S | — | 698,561.64 | 475,683.08 | 1,696,180.85 | 228.59 | — | — | — | — | — | 0.00 | 717,663.5 | ||||||
| P/B | — | 0.00 | 0.00 | 44,524.93 | 1.53 | — | — | — | — | — | 0.00 | 11,131.6 | ||||||
| EV/Sales | — | 698,571.16 | 475,702.12 | 1,696,179.64 | 222.99 | — | — | — | — | — | 63.80 | 717,669.0 | ||||||
| EV/FCF | — | (42,150.00) | (33,528.77) | (192,288.18) | (4.50) | — | — | — | — | — | (2.12) | (66,992.9) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | (34) | (21) | (16) | (25) | (25) | (24) | (19) | (13) | (15) | (15) | (9.3%) | |||||
| Capex | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (31.7%) | ||||||
| Free cash flow | — | (34) | (21) | (16) | (25) | (26) | (24) | (19) | (13) | (15) | (15) | (9.4%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | (6) | (10) | 5 | 16 | 12 | 19 | 5 | 1 | (3) | (15) | (8.1%) | |||||
| Net debt | — | 19 | 13 | (2) | (3) | 1 | (7) | 9 | 11 | (1) | 17 | n/m | ||||||
| Shareholders’ equity | — | (29) | (24) | 68 | 75 | 70 | 42 | 10 | 3 | 10 | (12) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | (146.05) | (380.44) | (56.63) | (23.05) | (28.09) | (72.08) | (69.55) | (57.68) | (18.20) | (210.34) | +127.9 pt | |||||
| ROIC | — | 0.00 | 0.00 | (15.35) | (21.57) | (26.92) | (138.69) | (135.31) | (89.99) | (178.02) | (386.34) | (178.0) pt | ||||||
| ROE | — | 384.07 | 94.09 | (157.29) | (38.41) | (45.08) | (121.39) | (151.11) | (302.78) | (81.98) | 1,356.23 | (466.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | 49 | 29 | 33 | 32 | 31 | 33 | 20 | 15 | 14 | — | (14.5%) | |||||
| Revenue/emp, $m | — | 0.04 | 0.05 | 0.05 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2019 · latest quarter Dec 2019 · fundamentals updated 26 Oct 2026
Windtree Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NRSN NeuroSense Therapeutics Ltd. | $2.6M | — (loss-making) | — | — | n/m | −23,458.82% (below 0%: shrinking) | — | 0.00% | Compare |
| EOCN Eocene Ltd. | $2.6M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −67.74% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| BIORQ Biora Therapeutics, Inc. | $2.5M | — (loss-making) | — (loss-making) | +1,500.00% (above 0%: growing) | n/m | +20.72% (above 0%: growing) | 100.00% | (50,709.38%) | Compare |
| CLDI Calidi Biotherapeutics, Inc. | $2.5M | — (loss-making) | — | — | n/m | +11.16% (above 0%: growing) | — | 0.00% | Compare |
| WINT Windtree Therapeutics, Inc. | $2.4M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | +1.12% (above 0%: growing) | 0.00% | 0.00% | |
| VIVS VivoSim Labs, Inc. | $2.3M | — (loss-making) | — (loss-making) | −51.35% (below 0%: shrinking) | n/m | +17.87% (above 0%: growing) | 100.00% | (15,327.78%) | Compare |
| HCWB HCW Biologics Inc. | $2.3M | — (loss-making) | — (loss-making) | +1,954.55% (above 0%: growing) | n/m | −20.84% (below 0%: shrinking) | (69.25%) | (2,335.03%) | Compare |
| APVO Aptevo Therapeutics Inc. | $2.3M | — (loss-making) | — (loss-making) | +28.62% (above 0%: growing) | n/m | +23.11% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SLXN Silexion Therapeutics Corp | $2.2M | — (loss-making) | — | — | n/m | −16.63% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $2.4M | — | — | +28.62% | — | −2.73% | 0.00% | 0.00% |